PACB Pacific Biosciences Of California Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PACB

Price (delayed)

$2.135

Market cap

$581.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

$1.44B

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
The quick ratio has soared by 138% YoY and by 16% from the previous quarter
The revenue has increased by 50% YoY
The gross margin has contracted by 19% YoY but it has grown by 3% from the previous quarter
The company's equity fell by 7% QoQ and by 6% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.pacb.com
Peers: ILMN GE TMO

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
272.36M
Market cap
$581.48M
Enterprise value
$1.44B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
2.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.16
Earnings
Revenue
$200.43M
EBIT
-$294.03M
EBITDA
-$260M
Free cash flow
-$249.17M
Per share
EPS
-$1.14
Free cash flow per share
-$0.92
Book value per share
$2.42
Revenue per share
$0.74
TBVPS
$2.81
Balance sheet
Total assets
$1.67B
Total liabilities
$1.02B
Debt
$931.37M
Equity
$649.02M
Working capital
$604.07M
Liquidity
Debt to equity
1.44
Current ratio
9.28
Quick ratio
8.12
Net debt/EBITDA
-3.29
Margins
EBITDA margin
-129.7%
Gross margin
27.1%
Net margin
-148.1%
Operating margin
-160.6%
Efficiency
Return on assets
-16.6%
Return on equity
-43.1%
Return on invested capital
-20.1%
Return on capital employed
-18.4%
Return on sales
-146.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
11.78%
1 week
28.61%
1 month
58.15%
1 year
-83.8%
YTD
-78.24%
QTD
55.84%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$200.43M
Gross profit
$54.3M
Operating income
-$321.84M
Net income
-$296.9M
Gross margin
27.1%
Net margin
-148.1%
The revenue has increased by 50% YoY
The net margin is up by 38% year-on-year and by 3.2% since the previous quarter
PACB's operating margin is up by 29% year-on-year
Pacific Biosciences Of California's gross profit has increased by 22% YoY and by 2.9% QoQ

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
0.88
P/S
2.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.16
The EPS has grown by 18% YoY and by 6% from the previous quarter
The P/B is 91% below the 5-year quarterly average of 8.7 and 76% below the last 4 quarters average of 3.3
The company's equity fell by 7% QoQ and by 6% YoY
The price to sales (P/S) is 89% lower than the 5-year quarterly average of 22.9 and 81% lower than the last 4 quarters average of 13.2
The revenue has increased by 50% YoY

Efficiency

How efficient is Pacific Biosciences Of California business performance
The ROS has grown by 36% YoY and by 3.2% from the previous quarter
The ROE has grown by 14% YoY
The company's return on invested capital rose by 6% QoQ and by 3.4% YoY
PACB's ROA is up by 4.6% YoY

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The company's total assets is 64% higher than its total liabilities
The company's current ratio has surged by 151% YoY and by 19% QoQ
The quick ratio has soared by 138% YoY and by 16% from the previous quarter
The debt is 44% greater than the equity
The company's debt to equity rose by 8% QoQ and by 5% YoY
The company's equity fell by 7% QoQ and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.